Balancing efficacy and safety in treatment with antipsychotics

被引:65
作者
Correll, Christoph U. [1 ]
机构
[1] Zucker Hillside Hosp Queens, Recognit & Prevent Program, New York, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
D O I
10.1017/S1092852900026298
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Balancing efficacy with tolerability and safety of prescribed treatments is critical to optimizing antipsychotic treatment outcomes in the mentally ill. Symptom control, symptom remission, and functional recovery are only realistic goals when treatments are both effective and well tolerated. The consideration of predictable differences in antipsychotic adverse-effect profiles is central to successful illness management. Minimizing adverse effects on alertness, motivation, cognition, sexual/reproductive functioning, and physical health enhances mental health outcomes, partly through improving treatment adherence. Neuroendocrine and metabolic side effects of antipsychotics for cardiovascular morbidity and mortality need to be addressed proactively and aggressively. In view of the widespread lack of primary care engagement and the adverse effects of psychotropic medications on cardiovascular health, psychiatric care providers should function as key facilitators of an integrated mental and physical health management approach. In addition to psychoeducation and healthy lifestyle counseling, clinicians can improve psychiatric and physical health by selecting medications carefully, routinely screening and monitoring for reversible cardiovascular risk factors, and playing an active role in the prevention and interdisciplinary management of cardiovascular risk factors and medical illness in the vulnerable mentally ill.
引用
收藏
页码:12 / +
页数:10
相关论文
共 107 条
[1]   Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial [J].
Addington, DEN ;
Pantelis, C ;
Dineen, M ;
Benattia, I ;
Romano, SJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (12) :1624-1633
[2]   Early use of clozapine for poorly responding first-episode psychosis [J].
Agid, Ofer ;
Remington, Gary ;
Kapur, Shitij ;
Arenovich, Tamara ;
Zipursky, Robert B. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (04) :369-373
[3]   SCHIZOPHRENIA - A LIFE-SHORTENING DISEASE [J].
ALLEBECK, P .
SCHIZOPHRENIA BULLETIN, 1989, 15 (01) :81-89
[4]   The distribution of body mass index among individuals with and without schizophrenia [J].
Allison, DB ;
Fontaine, KR ;
Heo, M ;
Mentore, JL ;
Cappelleri, JC ;
Chandler, LP ;
Weiden, PJ ;
Cheskin, LJ .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (04) :215-220
[6]   A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia [J].
Azorin, JM ;
Spiegel, R ;
Remington, G ;
Vanelle, JM ;
Péré, JJ ;
Giguere, M ;
Bourdeix, I .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) :1305-1313
[7]   Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease [J].
Bassuk, SS ;
Manson, JE .
JOURNAL OF APPLIED PHYSIOLOGY, 2005, 99 (03) :1193-1204
[8]   Atypical antipsychotics and glucose homeostasis [J].
Bergman, RN ;
Ader, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (04) :504-514
[9]   The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: A comparative study [J].
Birkenaes, Astrid B. ;
Opjordsmoen, Stein ;
Brunborg, Cathrine ;
Engh, John A. ;
Jonsdottir, Halldora ;
Ringen, P. Andreas ;
Simonsen, Carmen ;
Vaskinn, Anja ;
Birkeland, Kare I. ;
Friis, Svein ;
Sundet, Kjetil ;
Andreassen, Ole A. .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (06) :917-923
[10]   Clinicians' recognition of the metabolic adverse effects of antipsychotic medications [J].
Buckley, PF ;
Miller, DD ;
Singer, B ;
Arena, J ;
Stirewalt, EM .
SCHIZOPHRENIA RESEARCH, 2005, 79 (2-3) :281-288